Status:
COMPLETED
Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers
Lead Sponsor:
Zagazig University
Conditions:
Non-melanoma Skin Cancers
Eligibility:
All Genders
20-90 years
Phase:
PHASE2
Brief Summary
to compare the effectiveness and safety of intralesional vs. systemic MTX in NMSC management
Detailed Description
Intralesional methotrexate (MTX) could to be promising conservative alternative for non-melanoma skin cancer (NMSC). Systemic MTX was attempted as adjuvant for locally-advanced NMSC.
Eligibility Criteria
Inclusion
- • Adult patients of both sexes with histologically-confirmed primary or recurrent non- metastatic NMSCs of different types (BCC,SCC, and/or KA), sites, number, sizes and duration were included in the study.
Exclusion
- • Hypersensitivity reactions to methotrexate, liver or kidney disease, immunosuppressive conditions, HIV, HBV, and HCV infection, hematological abnormalities and metastasis. Pregnant or lactating women, females in their child-bearing period not using or refusing contraceptive methods, and those who had any other form of NMSC management in the month preceding enrollment.
Key Trial Info
Start Date :
July 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 6 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05315128
Start Date
July 6 2020
End Date
December 6 2021
Last Update
April 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig university
Zagazig, Sharqia Province, Egypt, 44519